EP3723743A4 - Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique - Google Patents
Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique Download PDFInfo
- Publication number
- EP3723743A4 EP3723743A4 EP18915505.4A EP18915505A EP3723743A4 EP 3723743 A4 EP3723743 A4 EP 3723743A4 EP 18915505 A EP18915505 A EP 18915505A EP 3723743 A4 EP3723743 A4 EP 3723743A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- dapoxetine
- inhibitor
- pharmaceutical combination
- phosphodiesterase type
- emetic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title 1
- 239000002111 antiemetic agent Substances 0.000 title 1
- 229940125683 antiemetic agent Drugs 0.000 title 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 title 1
- 229960005217 dapoxetine Drugs 0.000 title 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR201720443 | 2017-12-15 | ||
| PCT/TR2018/050806 WO2019203753A2 (fr) | 2017-12-15 | 2018-12-13 | Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3723743A2 EP3723743A2 (fr) | 2020-10-21 |
| EP3723743A4 true EP3723743A4 (fr) | 2021-09-08 |
Family
ID=68240624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18915505.4A Withdrawn EP3723743A4 (fr) | 2017-12-15 | 2018-12-13 | Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3723743A4 (fr) |
| WO (1) | WO2019203753A2 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250206757A1 (en) | 2022-03-21 | 2025-06-26 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| TW202435857A (zh) | 2022-12-15 | 2024-09-16 | 美商迦舒布魯姆生物有限公司 | 具有glp-1促效劑活性之化合物之鹽及固體形式 |
| WO2024131869A1 (fr) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques du glp-1 |
| JP2026501286A (ja) | 2022-12-22 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式glp-1アゴニスト |
| CN120957993A (zh) | 2023-02-16 | 2025-11-14 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| CN116672330A (zh) * | 2023-06-28 | 2023-09-01 | 郑州德迈药业有限公司 | 一种盐酸达泊西汀复合物及其口溶膜 |
| EP4735456A1 (fr) | 2023-06-30 | 2026-05-06 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques de glp-1 |
| AR133240A1 (es) | 2023-07-13 | 2025-09-10 | Aconcagua Bio Inc | Compuestos, composiciones y métodos |
| TW202519220A (zh) | 2023-07-13 | 2025-05-16 | 美商雅空嘉閣生物公司 | 化合物、組合物及方法 |
| WO2025045208A1 (fr) | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Agonistes de glp-1 à base de hétéroaryl-hétérocycloalkyl |
| WO2025137307A1 (fr) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques de glp-1 |
| WO2025171341A2 (fr) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Composés et compositions pour traiter des états associés au récepteur de la calcitonine et/ou à l'activité du récepteur de l'amyline |
| WO2025171340A1 (fr) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Traitement d'états associés au récepteur de la calcitonine et/ou de l'amyline |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2026041075A1 (fr) | 2024-08-21 | 2026-02-26 | Gasherbrum Bio, Inc. | Agonistes de gpl-1 |
| WO2026051998A1 (fr) | 2024-09-04 | 2026-03-12 | Aconcagua Bio, Inc. | Composés, compositions et procédés |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020037828A1 (en) * | 1997-10-28 | 2002-03-28 | Wilson Leland F. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US20150202168A1 (en) * | 2012-08-17 | 2015-07-23 | Sanovel llac Sanayi Ve Ticaret Anonim Sirketi | Oral film formulations comprising dapoxetine and tadalafil |
-
2018
- 2018-12-13 WO PCT/TR2018/050806 patent/WO2019203753A2/fr not_active Ceased
- 2018-12-13 EP EP18915505.4A patent/EP3723743A4/fr not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020037828A1 (en) * | 1997-10-28 | 2002-03-28 | Wilson Leland F. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US20150202168A1 (en) * | 2012-08-17 | 2015-07-23 | Sanovel llac Sanayi Ve Ticaret Anonim Sirketi | Oral film formulations comprising dapoxetine and tadalafil |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3723743A2 (fr) | 2020-10-21 |
| WO2019203753A2 (fr) | 2019-10-24 |
| WO2019203753A3 (fr) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3723743A4 (fr) | Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique | |
| EP3805264A4 (fr) | Anticorps anti-interleukine 17a, composition pharmaceutique et utilisation associées | |
| EP3749317A4 (fr) | Pémétrexed alpha-polyglutamaté et utilisations associées | |
| EP3741374A4 (fr) | Inhibiteur de mtor, composition pharmaceutique et son utilisation | |
| EP3706741A4 (fr) | Composition pharmaceutique et utilisation associée | |
| IL287905A (en) | A pharmaceutical preparation containing brexanolone, gnaxolone or zoranolone and its use | |
| GB2606804B (en) | Benzenesulfonamide derivatives and uses thereof | |
| SG11201908281VA (en) | Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof | |
| SG11202101435XA (en) | ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| EP3904429A4 (fr) | Poudre de cellulose, son utilisation et comprimé | |
| EP3966223A4 (fr) | Agents peptidomimétiques, synthèse et utilisations de ceux-ci | |
| EP3694519A4 (fr) | Combinaison pharmaceutique comprenant de la dapoxétine et de la phosphodiestérase de type 5 | |
| EP3670500A4 (fr) | Composé chimique, composition pharmaceutique de celui-ci, utilisation et application correspondantes | |
| EP3993818A4 (fr) | Agent de liaison à cd38 et utilisations associées | |
| EP3999056A4 (fr) | Combinaison pharmaceutique et son utilisation | |
| EP3993874A4 (fr) | Agents de liaison à cd38 et leurs utilisations | |
| SG11202103806VA (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| PT3755685T (pt) | Derivados de denatónio de aminometilo funcionalizado e respetivas preparação e utilização | |
| EP4023642A4 (fr) | Inhibiteur de jnk, et composition pharmaceutique et utilisation associée | |
| EP3301095A4 (fr) | Nouvel inhibiteur de la phosphodiestérase de type 5 et son application | |
| HK40077814A (en) | Pharmaceutical combination and use thereof | |
| HK40071214A (en) | Thienoazepine immunoconjugates, and uses thereof | |
| HK40069872A (en) | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof | |
| HK40082383A (en) | Retrotransposons and use thereof | |
| HK40067178A (en) | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200323 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TUERKYILMAZ, ALI. Inventor name: PALATOEKEN, ARZU. Inventor name: GUENER, DICLE. |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20210811 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/166 20060101ALI20210805BHEP Ipc: A61K 31/519 20060101ALI20210805BHEP Ipc: A61K 31/4985 20060101ALI20210805BHEP Ipc: A61K 9/20 20060101ALI20210805BHEP Ipc: A61K 31/138 20060101AFI20210805BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20220311 |